These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25865683)

  • 1. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
    Kasuga A; Hamamoto Y; Takeuchi A; Okano N; Togasaki K; Aoki Y; Suzuki T; Kawasaki K; Hirata K; Sukawa Y; Kanai T; Takaishi H
    Invest New Drugs; 2018 Oct; 36(5):939-948. PubMed ID: 29572783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
    Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
    Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
    Makris EA; MacBarb R; Harvey DJ; Poultsides GA
    Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.
    Colloca G; Venturino A; Guarneri D
    Clin Colorectal Cancer; 2016 Sep; 15(3):264-76. PubMed ID: 26776098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
    Bria E; Milella M; Gelibter A; Cuppone F; Pino MS; Ruggeri EM; Carlini P; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2007 Aug; 110(3):525-33. PubMed ID: 17577216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.
    Kasuga A; Hamamoto Y; Takeuchi A; Kawasaki K; Suzuki T; Hirata K; Sukawa Y; Takaishi H; Kanai T
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):595-602. PubMed ID: 28236000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
    Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
    World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
    Moriwaki T; Yamamoto Y; Gosho M; Kobayashi M; Sugaya A; Yamada T; Endo S; Hyodo I
    Br J Cancer; 2016 Apr; 114(8):881-8. PubMed ID: 27031848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.